BioCentury | Jun 11, 2015
Distillery Therapeutics

Therapeutics: Phosphoribosyl pyrophosphate synthetase 1 (PRPS1)

Cancer INDICATION: Acute lymphoblastic leukemia (ALL) In vitro studies suggest the purine synthesis inhibitor lometrexol could help treat thiopurine-resistant ALL. In ALL cells from 358 patients who relapsed after thiopurine therapy, whole-genome sequencing identified PRPS1...
BioCentury | Jun 26, 2014
Distillery Therapeutics

Indication: Cancer

...Licensing status Publication and contact information Cancer Cancer c-Myc (MYC); phosphoribosyl pyrophosphate synthetase 2 (PRPS2) Mouse studies suggest inhibiting PRPS2...
...of Prps2, a rate-limiting enzyme for the synthesis of purines. In the model, knockout of Prps2...
...steps include antagonizing PRPS2 in additional MYC-driven tumor types and developing a specific inhibitor of PRPS2...
BioCentury | Jun 19, 2014
Cover Story

Breaking MYC metabolism

...protein translation was directly coupled to nucleotide biosynthesis and that the rate-limiting enzyme was Prps2. PRPS2...
...Prps2 mRNA, thus providing a mechanism for its regulation by Myc. Importantly, genetic knockout of Prps2...
...by the loss of Prps2 is the presence of Prps1, which shares 95% homology with Prps2...
BioCentury | Jan 17, 2011
Product Development

Enabling patient PRPs

After securing exclusive rights to an in vivo , patient-based screening platform for cancer-specific peptide-receptor pairs, Mercator Therapeutics Inc. needed a source of optimized peptides and antibodies. A pair of deals this month gives the biotech...
Items per page:
1 - 4 of 4